|
|
| Press Releases |
Tuesday, March 03, 2009
Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
Read More> |
 |
Wednesday, January 07, 2009
Intellect Neurosciences, Inc. Grants Top Tier Global Pharmaceutical Company License to Certain Alzheimer's Patents and Patent Applications
Read More> |
|
Friday, November 21, 2008
Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO
Read More> |
|
Tuesday, November 11, 2008
Intellect Neurosciences, Inc. Validates Pivotal European Patent for Alzheimer's
Read More> |
|
Wednesday, October 08, 2008
Intellect Neurosciences, Inc. Grants to Top Tier Global Pharmaceutical Company an Option to License Certain Alzheimer's Patents and Patent Applications
Read More> |
|
Thursday, July 31, 2008
Intellect Neurosciences, Inc. Obtains Pivotal European Patent Related To Monoclonal Antibody Passive Immunization Treatment Of Alzheimer's Disease
Read More> |
|
Tuesday, June 24, 2008
Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimer's Therapeutic Antibody
Read More> |
|
Monday, May 19, 2008
Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
Read More> |
|
Thursday, April 10, 2008
Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer's Disease
Read More> |
|
Thursday, September 20, 2007
Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
Read More> |
|
Wednesday, September 19, 2007
Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimer’s Vaccine in 19 Countries
Read More> |
|
Monday, August 20, 2007
Intellect Neurosciences, Inc. to Present Data on Alzheimer's Vaccine at 13th International Congress of Immunology Conference
Read More> |
|
Tuesday, August 07, 2007
Intellect Neurosciences, Inc. CEO to Be Interviewed By Market News First
Read More> |
|
Monday, August 06, 2007
Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Enter into Agreement to Humanize Two Monoclonal Antibodies for the Treatment of Alzheimer's Disease
Read More> |
|
Monday, July 30, 2007
Intellect Neurosciences, Inc. Announces the Release of Audited Data for its Drug Candidate, OXIGON(TM), From a Single Dose Phase I Trial
Read More> |
|
Friday, July 27, 2007
Intellect Neurosciences, Inc. Appoints Dr. Thomas M. Wisniewski, M.D. to its Clinical Advisory Board
Read More> |
|
Friday, June 29, 2007
Intellect Neurosciences, Inc. Appoints William Keane and Elliot Maza to its Board of Directors
Read More> |
|
Monday, June 25, 2007
Intellect Neurosciences, Inc. Obtains Validation of European Patent for Clinical Candidate in 18 CountriesProtection of OXIGON(TM) for Multiple Medical Indications including Alzheimer's Disease
Read More> |
|
Thursday, June 14, 2007
Intellect Neurosciences, Inc. Common Stock Commences Trading Under Symbol
Read More> |
|
Thursday, February 01, 2007
Intellect Neurosciences, Inc. Converts into a Public Company through Merger Transaction with Globepan Resources, Inc.
Read More> |
|
Thursday, January 11, 2007
Immuno-Biological Laboratories, Ltd. and Intellect Neurosciences, Inc Enter into Humanized Monoclonal Antibodies Development Agreement for the Treatment of Alzheimer’s Disease
Read More> |
|
Monday, March 03, 2003
Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
Read More> |
|
|
|
